HC Wainwright Predicts Higher Earnings for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Stock analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for BridgeBio Pharma in a research report issued to clients and investors on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.51) per share for the quarter, up from their previous estimate of ($0.54). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($1.69) EPS.

Several other research firms have also recently weighed in on BBIO. Oppenheimer boosted their price target on shares of BridgeBio Pharma from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Friday, February 13th. JPMorgan Chase & Co. boosted their target price on BridgeBio Pharma from $76.00 to $77.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Morgan Stanley started coverage on BridgeBio Pharma in a report on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 target price for the company. Piper Sandler increased their price target on BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Finally, Raymond James Financial set a $89.00 price objective on BridgeBio Pharma and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $82.05.

BridgeBio Pharma Price Performance

NASDAQ BBIO opened at $70.72 on Thursday. The company has a fifty day moving average price of $75.66 and a 200-day moving average price of $63.84. The firm has a market cap of $13.63 billion, a price-to-earnings ratio of -16.92 and a beta of 1.13. BridgeBio Pharma has a 1 year low of $28.33 and a 1 year high of $84.94.

Insider Buying and Selling at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 510 shares of BridgeBio Pharma stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total value of $37,898.10. Following the completion of the transaction, the chief accounting officer directly owned 123,945 shares in the company, valued at approximately $9,210,352.95. The trade was a 0.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Thomas Trimarchi sold 13,600 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total value of $1,016,192.00. Following the sale, the chief financial officer directly owned 336,585 shares in the company, valued at $25,149,631.20. This trade represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 176,121 shares of company stock worth $13,009,631. 18.20% of the stock is owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Large investors have recently modified their holdings of the company. Global Retirement Partners LLC increased its holdings in BridgeBio Pharma by 271.5% during the 4th quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock worth $39,000 after acquiring an additional 372 shares during the period. Farther Finance Advisors LLC grew its position in shares of BridgeBio Pharma by 91.4% during the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after purchasing an additional 245 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of BridgeBio Pharma in the fourth quarter worth $41,000. Cary Street Partners Investment Advisory LLC raised its position in shares of BridgeBio Pharma by 861.0% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 567 shares of the company’s stock worth $43,000 after buying an additional 508 shares in the last quarter. Finally, Eurizon Capital SGR S.p.A. purchased a new stake in shares of BridgeBio Pharma in the fourth quarter worth $44,000. 99.85% of the stock is currently owned by institutional investors.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL‑3 achondroplasia results improve the program’s regulatory and commercial outlook — a clear fundamental catalyst supporting upside for BBIO. Read More.
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and bumped its price target to $100 while keeping a Buy rating — analyst upgrades can lift sentiment and buying interest. Read More.
• Neutral Sentiment: Upcoming Q4/2025 earnings and Feb. 24 conference call create a scheduled event risk: results and program/cash‑burn details could drive short‑term volatility either way. Read More.
• Neutral Sentiment: Company granted inducement RSUs to new hires (76,701 shares) — modest ongoing dilution to monitor but not a large immediate overhang. Read More.
• Neutral Sentiment: Small institutional buying: Oppenheimer reported a new 7,845‑share stake per 13F filing — signals some investor interest but immaterial scale. Read More.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO sold 13,600 shares (~$1.02M), alongside other officer sales — concentrated disposals are pressuring near‑term sentiment. Read More.
• Negative Sentiment: Smaller CAO sale (510 shares) and a pattern of executive liquidity events — repeated sales by insiders can keep downward pressure until management rebuilds conviction via buying or other signals. Read More.
• Neutral Sentiment: Reported short‑interest data is inconsistent (entries show zero shares / NaN) and does not currently indicate a material short‑squeeze dynamic — treat the short‑interest note as noise until clearer reporting emerges.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.